Loading stock data…
RVMD
$139.48-4.64 (-3.22%)
Market ClosedLast close May 1
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revolution Medicines, Inc. in the Healthcare sector is trading at $139.48. The stock is currently near its 52-week high of $155.70, remaining 82.7% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why RVMD maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$139.48
Potential Upside
5%
Whystock Fair Value$146.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$174.30+25.0%
Range$116.00 – $263.00
Fundamentals
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.78%
Volume
Today's trading volume
2.57M
Recent News
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results
Tango Therapeutics stock has soared this year on its pancreatic cancer treatment combination with Revolution Medicines.
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges
Erasca reports patient death tied to severe side effects, while rival Revolution Medicines files patent claim and gains 10%.
Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?
Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis.
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.
A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patients with lung and pancreatic cancer. Investors quickly drew parallels to daraxonrasib, the high-profile lead asset from Revolution Medicines Daraxonrasib has been on the receiving end of a storm of media coverage following an endorsement from former Nebraska Sen. Ben Sasse.